ProMIS Neurosciences Announces At The Market Offering

ProMIS Neurosciences ( (PMN) ) has issued an announcement.

On August 13, 2025, ProMIS Neurosciences Inc. announced an At The Market Offering Agreement with H.C. Wainwright & Co, LLC, allowing the company to sell up to $17,988,524 of its common shares. This strategic move is designed to provide ProMIS with financial flexibility and potential capital to support its operations and growth in the competitive biotechnology sector.

The most recent analyst rating on (PMN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.

Spark’s Take on PMN Stock

According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.

ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.

To see Spark’s full report on PMN stock, click here.

More about ProMIS Neurosciences

ProMIS Neurosciences Inc. operates in the biotechnology industry, focusing on developing therapeutic solutions for neurodegenerative diseases. The company primarily offers products and services aimed at addressing conditions such as Alzheimer’s disease, leveraging its proprietary technology to target misfolded proteins.

Average Trading Volume: 7,093,900

Technical Sentiment Signal: Sell

Current Market Cap: $31.96M

Find detailed analytics on PMN stock on TipRanks’ Stock Analysis page.